A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.
CC chemokine receptors
CXC chemokine receptors
Multiple sclerosis
chemokine
Journal
Metabolic brain disease
ISSN: 1573-7365
Titre abrégé: Metab Brain Dis
Pays: United States
ID NLM: 8610370
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
19
05
2020
accepted:
16
11
2020
pubmed:
7
1
2021
medline:
28
10
2021
entrez:
6
1
2021
Statut:
ppublish
Résumé
Multiple sclerosis (MS) as a chronic inflammatory disorder of the central nervous system (CNS) is thought to be caused by the abnormal induction of immune responses. Chemokines as molecules that can engage leukocytes into the location of inflammation, actively participate in the pathogenesis of MS. Several members of this family of chemo attractants have been shown to be dysregulated in the peripheral blood, cerebrospinal fluid or CNS lesions of MS patients. Studies in animal models of MS particularly experimental autoimmune encephalomyelitis have indicated the critical roles of chemokines in the pathophysiology of MS. In the current review, we summarize the data regarding the role of CCL2, CCL3, CCL4, CCL11, CCL20, CXCL1, CXCL2, CXCL8, CXCL10, CXCL12 and CXCL13 in the pathogenesis of MS.
Identifiants
pubmed: 33404937
doi: 10.1007/s11011-020-00648-6
pii: 10.1007/s11011-020-00648-6
doi:
Substances chimiques
Chemokines
0
Receptors, Chemokine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
375-406Références
Almasi S, Aliparasti MR, Farhoudi M, Babaloo Z, Baradaran B, Zamani F, Sadeghi-Bazargani H, Mostafaei S, Hokmabadi ES (2013) Quantitative evaluation of CXCL8 and its receptors (CXCR1 and CXCR2) gene expression in Iranian patients with multiple sclerosis. Immunological investigations 42:737–748
pubmed: 23876169
doi: 10.3109/08820139.2013.812652
Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH (2013) CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Multiple Sclerosis Journal 19:1204–1208
pubmed: 23322500
doi: 10.1177/1352458512473362
Anastasiadou S, Liebenehm S, Sinske D, Meyer Zu Reckendorf C, Moepps B, Nordheim A, Knöll B (2015) Neuronal expression of the transcription factor serum response factor modulates myelination in a mouse multiple sclerosis model. Glia 63:958–976
pubmed: 25639799
doi: 10.1002/glia.22794
Archambault AS, Sim J, Mccandless EE, Klein RS, Russell JH (2006) Region-specific regulation of inflammation and pathogenesis in experimental autoimmune encephalomyelitis. Journal of neuroimmunology 181:122–132
pubmed: 17030428
doi: 10.1016/j.jneuroim.2006.08.012
Arima Y, Harada M, Kamimura D, Park J-H, Kawano F, Yull FE, Kawamoto T, Iwakura Y, Betz UA, Márquez G (2012) Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell 148:447–457
pubmed: 22304915
doi: 10.1016/j.cell.2012.01.022
Axelsson M, Malmeström C, Gunnarsson M, Zetterberg H, Sundström P, Lycke J, Svenningsson A (2014) Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Multiple Sclerosis Journal 20:43–50
pubmed: 23702432
doi: 10.1177/1352458513490544
Axelsson M, Mattsson N, Malmeström C, Zetterberg H, Lycke J (2013) The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. Journal of neuroimmunology 264:100–105
pubmed: 24125567
doi: 10.1016/j.jneuroim.2013.09.003
Azin H, Vazirinejad R, Ahmadabadi BN, Khorramdelazad H, Zarandi ER, Arababadi MK, Karimabad MN, Shamsizadeh A, Rafatpanah H, Hassanshahi G (2012) The SDF-1 3′ a genetic variation of the chemokine SDF-1α (CXCL12) in parallel with its increased circulating levels is associated with susceptibility to MS: a study on Iranian multiple sclerosis patients. Journal of Molecular Neuroscience 47:431–436
pubmed: 22125123
doi: 10.1007/s12031-011-9672-6
Babcock AA, Kuziel WA, Rivest S, Owens T (2003) Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. Journal of Neuroscience 23:7922–7930
pubmed: 12944523
doi: 10.1523/JNEUROSCI.23-21-07922.2003
Bartosik-Psujek H, Stelmasiak Z (2005) The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 12:49–54
pubmed: 15613147
doi: 10.1111/j.1468-1331.2004.00951.x
Bassi MS, Iezzi E, Landi D, Monteleone F, Gilio L, Simonelli I, Musella A, Mandolesi G, De Vito F, Furlan R (2018) Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course. Journal of neurology 265:2540–2547
doi: 10.1007/s00415-018-8994-5
Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L, Monsonego A, Bar-Shir A, Engel Y, Gozin M (2008) Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. The Journal of clinical investigation 118:1532–1543
pubmed: 18340379
pmcid: 2267014
doi: 10.1172/JCI33464
Becker S, Quay J, Koren HS, Haskill J (1994) Constitutive and stimulated MCP-1, GRO alpha, beta, and gamma expression in human airway epithelium and bronchoalveolar macrophages. American Journal of Physiology-Lung Cellular and Molecular Physiology 266:L278–L286
doi: 10.1152/ajplung.1994.266.3.L278
Bielekova B, Komori M, Xu Q, Reich DS, Wu T (2012) Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PloS one, 7
BlaževskI J, petković F, Momčilović M, Jevtić B, Stojković MM, Miljković D (2015) Tumor necrosis factor stimulates expression of CXCL12 in astrocytes. Immunobiology 220:845–850
pubmed: 25662914
doi: 10.1016/j.imbio.2015.01.007
Bose S, Cho J (2013) Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases. Archives of pharmacal research 36:1039–1050
pubmed: 23771498
doi: 10.1007/s12272-013-0161-z
Brenner P, Granqvist M, Königsson J, Al Nimer F, Piehl F, Jokinen J (2018) Depression and fatigue in multiple sclerosis: Relation to exposure to violence and cerebrospinal fluid immunomarkers. Psychoneuroendocrinology 89:53–58
pubmed: 29324301
doi: 10.1016/j.psyneuen.2018.01.002
Brettschneider, J., Czerwoniak, A., Senel, M., Fang, L., Kassubek, J., Pinkhardt, E., Lauda, F., Kapfer, T., Jesse, S. & Lehmensiek, V. 2010. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PloS one, 5.
Bsibsi M, Peferoen LA, Holtman IR, Nacken PJ, Gerritsen WH, Witte ME, Van Horssen J, Eggen BJ, Van Der Valk P, Amor S (2014) Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN-γ and alpha B-crystallin. Acta neuropathologica 128:215–229
pubmed: 24997049
doi: 10.1007/s00401-014-1317-8
Burman J, Svensson E, Fransson M, Loskog AS, Zetterberg H, Raininko R, Svenningsson A, Fagius J, Mangsbo SM (2014) The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention. Journal of neuroimmunology 277:153–159
pubmed: 25457841
doi: 10.1016/j.jneuroim.2014.10.005
Buschmann JP, Berger K, Awad H, Clarner T, Beyer C, Kipp M (2012) Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination. Journal of Molecular Neuroscience 48:66–76
pubmed: 22528463
pmcid: 3413816
doi: 10.1007/s12031-012-9773-x
Buttmann M, Merzyn C, Hofstetter HH, Rieckmann P (2007) TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-β treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. Journal of neuroimmunology 190:170–176
pubmed: 17884184
doi: 10.1016/j.jneuroim.2007.08.009
Buttmann M, Merzyn C, Rieckmann P (2004) Interferon-β induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. Journal of neuroimmunology 156:195–203
pubmed: 15465611
doi: 10.1016/j.jneuroim.2004.07.016
Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG (2001) B cells and professional APCs recruit regulatory T cells via CCL4. Nature immunology 2:1126–1132
pubmed: 11702067
doi: 10.1038/ni735
Calderon TM, Eugenin EA, Lopez L, Kumar SS, Hesselgesser J, RAINE CS, BERMAN JW (2006) A role for CXCL12 (SDF-1α) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. Journal of neuroimmunology 177:27–39
pubmed: 16782208
doi: 10.1016/j.jneuroim.2006.05.003
Campbell SJ, Meier U, Mardiguian S, Jiang Y, Littleton ET, Bristow A, Relton J, Connor TJ, Anthony DC (2010) Sickness behaviour is induced by a peripheral CXC-chemokine also expressed in multiple sclerosis and EAE. Brain, behavior, and immunity 24:738–746
pubmed: 20138139
doi: 10.1016/j.bbi.2010.01.011
Camperio C, Muscolini M, Volpe E, Di Mitri D, Mechelli R, Buscarinu MC, Ruggieri S, Piccolella E, Salvetti M, Gasperini C (2014) CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes. Immunology letters 158:134–142
pubmed: 24412596
doi: 10.1016/j.imlet.2013.12.020
Cedile O, Løbner M, Toft-Hansen H, Frank I, Wlodarczyk A, IRLA M, Owens T (2014) Thymic CCL2 influences induction of T-cell tolerance. Journal of autoimmunity 55:73–85
pubmed: 25129504
doi: 10.1016/j.jaut.2014.07.004
Cerutti C, Edwards LJ, De Vries HE, Sharrack B, Male DK, Romero IA (2017) MiR-126 and miR-126* regulate shear-resistant firm leukocyte adhesion to human brain endothelium. Scientific reports 7:1–14
doi: 10.1038/srep45284
Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. New England Journal of Medicine 354:610–621
doi: 10.1056/NEJMra052723
Chen Y, Langrish CL, Mckenzie B, Joyce-Shaikh B, Stumhofer JS, Mcclanahan T, Blumenschein W, Churakovsa T, Low J, Presta L (2006) Anti–IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. The Journal of clinical investigation 116:1317–1326
pubmed: 16670771
pmcid: 1450386
doi: 10.1172/JCI25308
Cheng W, Chen G (2014a) Chemokines and chemokine receptors in multiple sclerosis. Mediators of inflammation, 2014.
Cheng W, Chen G (2014b) Chemokines and chemokine receptors in multiple sclerosis. Mediators of inflammation 2014:659206–659206
pubmed: 24639600
pmcid: 3930130
Christensen JR, Ratzer R, Börnsen L, Lyksborg M, Garde E, Dyrby TB, Siebner HR, Sorensen PS, Sellebjerg F (2014) Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology 82:1499–1507
doi: 10.1212/WNL.0000000000000361
Comabella M, Imitola J, Weiner HL, Khoury SJ (2002) Interferon-β treatment alters peripheral blood monocytes chemokine production in MS patients. Journal of neuroimmunology 126:205–212
pubmed: 12020972
doi: 10.1016/S0165-5728(02)00064-4
Conroy DM, Williams TJ (2001) Eotaxin and the attraction of eosinophils to the asthmatic lung. Respiratory research 2:150
pubmed: 11686879
pmcid: 2002069
doi: 10.1186/rr52
Cross AK, Woodroofe MN (1999) Chemokines induce migration and changes in actin polymerization in adult rat brain microglia and a human fetal microglial cell line in vitro. Journal of neuroscience research 55:17–23
pubmed: 9890430
doi: 10.1002/(SICI)1097-4547(19990101)55:1<17::AID-JNR3>3.0.CO;2-J
Curran NM, Griffin BD, O'toole D, Brady KJ, Fitzgerald SN, Moynagh PN (2005) The synthetic cannabinoid R (+) WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. Journal of Biological Chemistry 280:35797–35806
doi: 10.1074/jbc.M507959200
D'aversa TG, Eugenin EA, Lopez L, Berman JW (2013) Myelin basic protein induces inflammatory mediators from primary human endothelial cells and blood–brain barrier disruption: implications for the pathogenesis of multiple sclerosis. Neuropathology and applied neurobiology 39:270–283
pubmed: 22524708
pmcid: 3430818
doi: 10.1111/j.1365-2990.2012.01279.x
Daugherty DJ, Chechneva O, Mayrhofer F, Deng W (2016) The hGFAP-driven conditional TSPO knockout is protective in a mouse model of multiple sclerosis. Scientific reports 6:1–7
doi: 10.1038/srep22556
Dixit N, Simon SI (2012) Chemokines, selectins and intracellular calcium flux: temporal and spatial cues for leukocyte arrest. Frontiers in immunology 3:188–188
pubmed: 22787461
pmcid: 3392659
doi: 10.3389/fimmu.2012.00188
Dolati S, Ahmadi M, Aghebti-Maleki L, Nikmaram A, Marofi F, Rikhtegar R, Ayromlou H, Yousefi M (2018) Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators. Pharmacological Reports 70:1158–1167
pubmed: 30340096
doi: 10.1016/j.pharep.2018.05.008
Draheim T, Liessem A, Scheld M, Wilms F, Weissflog M, Denecke B, Kensler TW, Zendedel A, Beyer C, Kipp M (2016) Activation of the astrocytic Nrf2/ARE system ameliorates the formation of demyelinating lesions in a multiple sclerosis animal model. Glia 64:2219–2230
pubmed: 27641725
doi: 10.1002/glia.23058
Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD (2002) IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. The Journal of Immunology 168:3195–3204
pubmed: 11907072
doi: 10.4049/jimmunol.168.7.3195
Eggers EL, Michel BA, Wu H, Wang S-Z, Bevan CJ, Abounasr A, Pierson NS, Bischof A, Kazer M, Leitner E (2017) Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. JCI insight 2
El Sharkawi FZ, Ali SA, Hegazy MI, Atya HB (2019) The combined effect of IL-17F and CCL20 gene polymorphism in susceptibility to multiple sclerosis in Egypt. Gene 685:164–169
pubmed: 30399422
doi: 10.1016/j.gene.2018.11.006
Ferraro D, Galli V, Vitetta F, Simone AM, Bedin R, Del Giovane C, Morselli F, Filippini MM, Nichelli PF, Sola P (2015) Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: association with oligoclonal IgM bands and prediction of multiple sclerosis diagnosis. Journal of neuroimmunology 283:64–69
pubmed: 26004159
doi: 10.1016/j.jneuroim.2015.04.011
Festa ED, Hankiewicz K, Kim S, Skurnick J, Wolansky LJ, Cook SD, Cadavid D (2009) Serum levels of CXCL13 are elevated in active multiple sclerosis. Multiple Sclerosis Journal 15:1271–1279
pubmed: 19805441
doi: 10.1177/1352458509107017
Fischer HJ, Schweingruber N, Lühder F, Reichardt HM (2013) The potential role of T cell migration and chemotaxis as targets of glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Molecular and cellular endocrinology 380:99–107
pubmed: 23578583
doi: 10.1016/j.mce.2013.04.001
Fischer, I., Alliod, C., Martinier, N., Newcombe, J., Brana, C. & Pouly, S. 2011. Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions. PloS one, 6.
Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A (2017) Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. Annals of neurology 82:186–195
pubmed: 28681388
doi: 10.1002/ana.24987
Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V (2001) Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. Journal of neuroimmunology 115:192–198
pubmed: 11282170
doi: 10.1016/S0165-5728(01)00261-2
Franciotta D, Zardini E, Ravaglia S, Piccolo G, Andreoni L, Bergamaschi R, Romani A, Tavazzi E, Naldi P, Ceroni M (2006) Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis. Journal of the neurological sciences 247:202–207
pubmed: 16784758
doi: 10.1016/j.jns.2006.05.049
Galimberti D, Scalabrini D, Fenoglio C, Comi C, De Riz M, Venturelli E, Lovati C, Mariani C, Monaco F, Bresolin N (2007) CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. European journal of neurology 14:162–167
pubmed: 17250724
doi: 10.1111/j.1468-1331.2006.01629.x
Gandhi KS, Mckay FC, Diefenbach E, Crossett B, Schibeci SD, Heard RN, Stewart GJ, Booth DR, Arthur JW (2010) Novel approaches to detect serum biomarkers for clinical response to interferon-β treatment in multiple sclerosis. PLoS One 5
Gerzanich V, Makar TK, Guda PR, Kwon MS, Stokum JA, Woo SK, Ivanova S, Ivanov A, Mehta RI, morris AB (2017) Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis. Journal of neuroinflammation 14:177
pubmed: 28865458
pmcid: 5581426
doi: 10.1186/s12974-017-0953-z
Giunti D, Borsellino G, Benelli R, Marchese M, Capello E, Valle MT, Pedemonte E, Noonan D, Albini A, Bernardi G (2003) Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. Journal of leukocyte biology 73:584–590
pubmed: 12714572
doi: 10.1189/jlb.1202598
Glabinski A, Bielecki B, Ransohoff R (2003) Chemokine upregulation follows cytokine expression in chronic relapsing experimental autoimmune encephalomyelitis. Scandinavian journal of immunology 58:81–88
pubmed: 12828562
doi: 10.1046/j.1365-3083.2003.01285.x
Glasnović A, Stojić M, Dežmalj L, Tudorić-Đeno I, Romić D, Jeleč V, Vrca A, Vuletić V, Grčević D (2018) RANKL/RANK/OPG Axis Is Deregulated in the Cerebrospinal Fluid of Multiple Sclerosis Patients at Clinical Onset. Neuroimmunomodulation 25:23–33
pubmed: 29920500
doi: 10.1159/000488988
Grist JJ, Marro BS, Skinner DD, Syage AR, Worne C, Doty DJ, Fujinami RS, Lane TE (2018) Induced CNS expression of CXCL1 augments neurologic disease in a murine model of multiple sclerosis via enhanced neutrophil recruitment. European journal of immunology 48:1199–1210
pubmed: 29697856
pmcid: 6033633
doi: 10.1002/eji.201747442
Haas J, Bekeredjian-Ding I, Milkova M, Balint B, Schwarz A, Korporal M, Jarius S, Fritz B, Lorenz H-M, Wildemann B (2011) B cells undergo unique compartmentalized redistribution in multiple sclerosis. Journal of autoimmunity 37:289–299
pubmed: 21924866
doi: 10.1016/j.jaut.2011.08.003
Hedges JC, Singer CA, Gerthoffer WT (2000) Mitogen-activated protein kinases regulate cytokine gene expression in human airway myocytes. American journal of respiratory cell and molecular biology 23:86–94
pubmed: 10873157
doi: 10.1165/ajrcmb.23.1.4014
Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R (2014) Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Multiple Sclerosis Journal 20:577–587
pubmed: 24009164
doi: 10.1177/1352458513503597
Hermanrud C, Ryner ML, Engdahl E, Fogdell-Hahn A (2014) Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point. Journal of Interferon & Cytokine Research 34:498–504
doi: 10.1089/jir.2013.0097
Herrmann MM, Barth S, Greve B, Schumann KM, Bartels A, Weissert R (2016) Identification of gene expression patterns crucially involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Disease models & mechanisms 9:1211–1220
doi: 10.1242/dmm.025536
Hieshima K, Imai T, Opdenakker G, Van Damme J, Kusuda J, Tei H, Sakaki Y, Takatsuki K, Miura R, Yoshie O (1997) Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver Chemotactic activity for lymphocytes and gene localization on chromosome 2. Journal of Biological Chemistry 272:5846–5853
doi: 10.1074/jbc.272.9.5846
Hinojosa AE, Garcia-Bueno B, Leza JC, Madrigal JL (2011) CCL2/MCP-1 modulation of microglial activation and proliferation. Journal of neuroinflammation 8:77
pubmed: 21729288
pmcid: 3146846
doi: 10.1186/1742-2094-8-77
Hosking, M. P., Tirotta, E., Ransohoff, R. M. & Lane, T. E. 2010. CXCR2 signaling protects oligodendrocytes and restricts demyelination in a mouse model of viral-induced demyelination. PloS one, 5.
Iarlori C, Reale M, DE Luca G, Di Iorio A, Feliciani C, Tulli A, Conti P, Gambi D, Lugaresi A (2002) Interferon β-1b modulates MCP-1 expression and production in relapsing–remitting multiple sclerosis. Journal of neuroimmunology 123:170–179
pubmed: 11880161
doi: 10.1016/S0165-5728(01)00487-8
Ifergan I, Wosik K, Cayrol R, Kébir H, Auger C, Bernard M, Bouthillier A, Moumdjian R, Duquette P, Prat A (2006) Statins reduce human blood–brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Annals of neurology 60:45–55
pubmed: 16729291
doi: 10.1002/ana.20875
Iida N, Grotendorst GR (1990) Cloning and sequencing of a new gro transcript from activated human monocytes: expression in leukocytes and wound tissue. Molecular and cellular biology 10:5596–5599
pubmed: 2078213
pmcid: 361282
doi: 10.1128/MCB.10.10.5596
Imai M, Watanabe M, Suyama K, Osada T, Sakai D, Kawada H, Matsumae M, Mochida J (2008) Delayed accumulation of activated macrophages and inhibition of remyelination after spinal cord injury in an adult rodent model. Journal of Neurosurgery: Spine 8:58–66
pubmed: 18173348
Iwanowski P, Losy J, Kramer L, Wójcicka M, Kaufman E (2017) CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis. Journal of the neurological sciences 380:22–26
pubmed: 28870573
doi: 10.1016/j.jns.2017.06.048
Jafarzadeh A, Arabi Z, Ahangar-Parvin R, Mohammadi-Kordkhayli M, Nemati M (2017) Ginger extract modulates the expression of chemokines CCL20 and CCL22 and their receptors (CCR6 and CCR4) in the central nervous system of mice with experimental autoimmune encephalomyelitis. Drug research 67:632–639
pubmed: 28672408
doi: 10.1055/s-0043-113455
Jafarzadeh A, Bagherzadeh S, Ebrahimi H, Hajghani H, Bazrafshani M, Khosravimashizi A, Nemati M, Gadari F, Sabahi A, Iranmanesh F (2014) Higher circulating levels of chemokine CCL20 in patients with multiple sclerosis: evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease pattern. Journal of Molecular Neuroscience 53:500–505
pubmed: 24395091
doi: 10.1007/s12031-013-0214-2
Javan MR, Shahraki S, Safa A, Zamani MR, Salmaninejad A, Aslani S (2017) An interleukin 12 B single nucleotide polymorphism increases IL-12p40 production and is associated with increased disease susceptibility in patients with relapsing-remitting multiple sclerosis. Neurol Res 39:435–441
pubmed: 28276258
doi: 10.1080/01616412.2017.1301623
Jee Y, Yoon WK, Okura Y, Tanuma N, Matsumoto Y (2002) Upregulation of monocyte chemotactic protein-1 and CC chemokine receptor 2 in the central nervous system is closely associated with relapse of autoimmune encephalomyelitis in Lewis rats. Journal of neuroimmunology 128:49–57
pubmed: 12098510
doi: 10.1016/S0165-5728(02)00147-9
Jiang W, St-Pierre S, Roy P, Morley BJ, Hao J, Simard AR (2016) Infiltration of CCR2+ Ly6Chigh proinflammatory monocytes and neutrophils into the central nervous system is modulated by nicotinic acetylcholine receptors in a model of multiple sclerosis. The Journal of Immunology 196:2095–2108
pubmed: 26810225
doi: 10.4049/jimmunol.1501613
Johnson TA, Lapierre Y, Bar-Or A, Antel JP (2010) Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis. Archives of neurology 67:1449–1455
pubmed: 21149809
doi: 10.1001/archneurol.2010.312
Kalinowska-Łyszczarz A, Szczuciński A, Pawlak MA, Losy J (2011) Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing− remitting multiple sclerosis patients. Journal of the neurological sciences 300:81–85
pubmed: 20947098
doi: 10.1016/j.jns.2010.09.026
Kamali-Sarvestani E, Nikseresht A-R, Aliparasti M-R, Vessal M (2006) IL-8 (− 251 A/T) and CXCR2 (+ 1208 C/T) gene polymorphisms and risk of multiple sclerosis in Iranian patients. Neuroscience letters 404:159–162
pubmed: 16793206
doi: 10.1016/j.neulet.2006.05.033
Kan Q-C, Zhu L, Liu N, Zhang G-X (2013) Matrine suppresses expression of adhesion molecules and chemokines as a mechanism underlying its therapeutic effect in CNS autoimmunity. Immunologic research 56:189–196
pubmed: 23549837
doi: 10.1007/s12026-013-8393-z
Kanayama M, Danzaki K, He Y-W, Shinohara ML (2016) Lung inflammation stalls Th17-cell migration en route to the central nervous system during the development of experimental autoimmune encephalomyelitis. International immunology 28:463–469
pubmed: 26989091
pmcid: 5006092
doi: 10.1093/intimm/dxw013
Karim H, Kim SH, Lapato AS, Yasui N, Katzenellenbogen JA, Tiwari-Woodruff SK (2018) Increase in chemokine CXCL1 by ERβ ligand treatment is a key mediator in promoting axon myelination. Proceedings of the National Academy of Sciences 115:6291–6296
doi: 10.1073/pnas.1721732115
Karpus WJ, Reynolds N, Behanna HA, Van Eldik LJ, Watterson DM (2008) Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug. Journal of neuroimmunology 203:73–78
pubmed: 18678415
pmcid: 2614915
doi: 10.1016/j.jneuroim.2008.06.039
Kawanokuchi J, Shimizu K, Nitta A, Yamada K, Mizuno T, Takeuchi H, Suzumura A (2008) Production and functions of IL-17 in microglia. Journal of neuroimmunology 194:54–61
pubmed: 18164424
doi: 10.1016/j.jneuroim.2007.11.006
Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA, Copeland NG, Bazan JF, Moore KW, Schall TJ (1994) Lymphotactin: a cytokine that represents a new class of chemokine. Science 266:1395–1399
pubmed: 7973732
doi: 10.1126/science.7973732
Kempe P, Eklund D, Hallin A, Hammar M, Olsson T, Brynhildsen J, Ernerudh J (2018) Immune profile in relation to sex steroid cyclicity in healthy women and women with multiple sclerosis. Journal of reproductive immunology 126:53–59
pubmed: 29501895
doi: 10.1016/j.jri.2018.02.006
Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, Hillert J, Piehl F, Olsson T (2011) Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Multiple Sclerosis Journal 17:335–343
pubmed: 21135023
doi: 10.1177/1352458510389102
Kleine TO, Zwerenz P, Graser C, Zöfel P (2003) Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-α, IL-1β, IL-6, IL-8. Brain research bulletin 61:327–346
pubmed: 12909303
doi: 10.1016/S0361-9230(03)00096-0
Komori M, Blake A, Greenwood M, Lin YC, Kosa P, Ghazali D, Winokur P, Natrajan M, Wuest SC, Romm E (2015) Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. Annals of neurology 78:3–20
pubmed: 25808056
pmcid: 5568079
doi: 10.1002/ana.24408
Kooij G, Kroon J, Paul D, Reijerkerk A, Geerts D, Van Der Pol SM, Van Het Hof B, Drexhage JA, Van Vliet SJ, Hekking LH (2014) P-glycoprotein regulates trafficking of CD8+ T cells to the brain parenchyma. Acta neuropathologica 127:699–711
pubmed: 24429546
doi: 10.1007/s00401-014-1244-8
Kooij G, Mizee MR, Van Horssen J, Reijerkerk A, Witte ME, Drexhage JA, Van Der Pol SM, Van Het Hof B, Scheffer G, Scheper R (2011) Adenosine triphosphate-binding cassette transporters mediate chemokine (CC motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. Brain 134:555–570
pubmed: 21183485
doi: 10.1093/brain/awq330
Kroner A, Mäurer M, Loserth S, Kleinschnitz C, Hemmer B, Rosche B, Toyka K, Rieckmann P (2004) Analysis of the monocyte chemoattractant protein 1− 2518 promoter polymorphism in patients with multiple sclerosis. Tissue Antigens 64:70–73
pubmed: 15191525
doi: 10.1111/j.1399-0039.2004.00240.x
Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, Ransohoff RM, Hofbauer M, Farina C, Derfuss T, Hartle C (2006) Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129:200–211
pubmed: 16280350
doi: 10.1093/brain/awh680
Kulakova OG, Tsareva EY, Lvovs D, Favorov AV, Boyko AN, Favorova OO (2014) Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate. Pharmacogenomics 15:679–685
pubmed: 24798724
doi: 10.2217/pgs.14.26
Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B (1998) B cell–attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. The Journal of experimental medicine 187:655–660
pubmed: 9463416
pmcid: 2212150
doi: 10.1084/jem.187.4.655
Lepennetier G, Hracsko Z, Unger M, Van Griensven M, Grummel V, Krumbholz M, Berthele A, Hemmer B, Kowarik MC (2019) Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. Journal of neuroinflammation 16:219
pubmed: 31727097
pmcid: 6857241
doi: 10.1186/s12974-019-1601-6
Lévesque SA, Paré A, Mailhot B, Bellver-Landete V, Kébir H, Lécuyer M-A, Alvarez JI, Prat A, Vaccari JPDR, Keane RW (2016) Myeloid cell transmigration across the CNS vasculature triggers IL-1β–driven neuroinflammation during autoimmune encephalomyelitis in mice. Journal of Experimental Medicine 213:929–949
doi: 10.1084/jem.20151437
Li R, Sun X, Shu Y, Wang Y, Xiao L, Wang Z, Hu X, Kermode AG, Qiu W (2017) Serum CCL20 and its association with SIRT1 activity in multiple sclerosis patients. Journal of neuroimmunology 313:56–60
pubmed: 29153609
doi: 10.1016/j.jneuroim.2017.10.013
Li R, Xu W, Chen Y, Qiu W, Shu Y, Wu A, Dai Y, Bao J, Lu Z, Hu X (2014) Raloxifene suppresses experimental autoimmune encephalomyelitis and NF-κB-dependent CCL20 expression in reactive astrocytes. PLoS One, 9.
Lindén M, Khademi M, Lima Bomfim I, Piehl F, Jagodic M, Kockum I, Olsson T (2013) Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13. Multiple sclerosis journal 19:863–870
pubmed: 23175382
doi: 10.1177/1352458512463482
Liston A, Kohler RE, Townley S, Haylock-Jacobs S, Comerford I, Caon AC, Webster J, Harrison JM, Swann J, Clark-Lewis I (2009) Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. The Journal of Immunology 182:3121–3130
pubmed: 19234209
doi: 10.4049/jimmunol.0713169
Lomakin, Y., Belogurov, A., Glagoleva, I., Stepanov, A., Zakharov, K., Okunola, J., Smirnov, I., Genkin, D. & Gabibov, A. 2016. Administration of myelin basic protein peptides encapsulated in mannosylated liposomes normalizes level of serum TNF-α and IL-2 and chemoattractants ccl2 and ccl4 in multiple sclerosis patients. Mediators of inflammation, 2016.
Losy J, Michałowska-Wender G, Wender M (2001) Chemokines MIP-1 and MCP-1 and patients with multiple sclerosis treated with interferon beta-1a. Neurologia i neurochirurgia polska 35:583–588
pubmed: 11783402
Lühder F, Kebir H, Odoardi F, Litke T, Sonneck M, Alvarez JI, Winchenbach J, Eckert N, Hayardeny L, Sorani E (2017) Laquinimod enhances central nervous system barrier functions. Neurobiology of disease 102:60–69
pubmed: 28235673
doi: 10.1016/j.nbd.2017.02.002
Luster AD, Unkeless JC, Ravetch JV (1985) γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315:672–676
pubmed: 3925348
doi: 10.1038/315672a0
Mahad D, Callahan MK, Williams KA, Ubogu EE, Kivisäkk P, Tucky B, Kidd G, Kingsbury GA, Chang A, Fox RJ (2006) Modulating CCR2 and CCL2 at the blood–brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129:212–223
pubmed: 16230319
doi: 10.1093/brain/awh655
Mahad DJ, Ransohoff RM (2003) The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Seminars in immunology, Elsevier, 23-32
Mahdavi R, Jamali M, Rostami M, Safa A, Jafarzadeh A, Naseri M (2016) FOXP3 polymorphism rs2232365 and its association with multiple sclerosis susceptibility. Tehran University Medical Journal TUMS Publications 74:425–432
MALMESTRÖM C, Andersson B, Haghighi S, Lycke J (2006) IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles. Journal of neuroimmunology 175:176–182
pubmed: 16626811
doi: 10.1016/j.jneuroim.2006.03.004
Martin NA, Nawrocki A, Molnar V, Elkjaer ML, Thygesen EK, Palkovits M, Acs P, Sejbaek T, Nielsen HH, Hegedus Z (2018) Orthologous proteins of experimental de-and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes. PloS one, 13
Martino G, Poliani PL, Furlan R, Marconi P, Glorioso JC, Adorini L, Comi G (2000) Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach. Journal of neuroimmunology 107:184–190
pubmed: 10854655
doi: 10.1016/S0165-5728(00)00236-8
Matejčíková Z, Mareš J, Sládková V, Svrčinová T, Vysloužilová J, Zapletalová J, Kaňovský P (2017) Cerebrospinal fluid and serum levels of interleukin-8 in patients with multiple sclerosis and its correlation with Q-albumin. Multiple sclerosis and related disorders 14:12–15
pubmed: 28619424
doi: 10.1016/j.msard.2017.03.007
Mayo L, Trauger SA, Blain M, Nadeau M, Patel B, Alvarez JI, Mascanfroni ID, Yeste A, Kivisäkk P, Kallas K (2014) Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nature medicine 20:1147
pubmed: 25216636
pmcid: 4255949
doi: 10.1038/nm.3681
Mccandless EE, Piccio L, Woerner BM, Schmidt RE, Rubin JB, Cross AH, Klein RS (2008) Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. The American journal of pathology 172:799–808
pubmed: 18276777
pmcid: 2258272
doi: 10.2353/ajpath.2008.070918
Mecha M, Feliú A, Iñigo P, Mestre L, Carrillo-Salinas F, Guaza C (2013) Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiology of disease 59:141–150
pubmed: 23851307
doi: 10.1016/j.nbd.2013.06.016
Mellergård J, Edström M, Vrethem M, Ernerudh J, Dahle C (2010) Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Multiple Sclerosis Journal 16:208–217
pubmed: 20007431
doi: 10.1177/1352458509355068
Mellergård J, Tisell A, Leinhard OD, Blystad I, Landtblom A-M, Blennow K, Olsson B, Dahle C, Ernerudh J, Lundberg P (2012) Association between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosis. PloS one, 7.
Messadi A, Fekih-Mrissa N, Kallel A, Bouguerra C, Sediri Y, Zaweli J, Laayouni S, Nciri B, Yedeas M, Mrissa R (2010) Lack of association between monocyte protein-1 (MCP-1)–2518 A> G chemoattractant and C–C chemokine receptor 2 (CCR2) Val64Ile polymorphisms and multiple sclerosis in a Tunisian population. Journal of Clinical Neuroscience 17:1311–1313
pubmed: 20637631
doi: 10.1016/j.jocn.2010.03.022
Michałowska-Wender G, Losy J, Biernacka-Łukanty J, Wender M (2008) Impact of methylprednisolone treatment on the expression of macrophage inflammatory protein 3alpha and B lymphocyte chemoattractant in serum of multiple sclerosis patients. Pharmacological reports: PR 60:549–554
pubmed: 18799824
Michałowska-Wender G, Losy J, Szczuciński A, Biernacka-Łukanty J, Wender M (2006) Effect of methylprednisolone treatment on expression of sPECAM-1 and CXCL10 chemokine in serum of MS patients. Pharmacological reports: PR 58:920–923
pubmed: 17220550
Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M (2001) Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. European Neuropsychopharmacology 11:203–208
pubmed: 11418279
doi: 10.1016/S0924-977X(01)00081-5
Miljković D, Stanojević Ž, Momcilović M, Odoardi F, Flügel A, Mostarica-Stojković M (2011) CXCL12 expression within the CNS contributes to the resistance against experimental autoimmune encephalomyelitis in Albino Oxford rats. Immunobiology 216:979–987
pubmed: 21601937
doi: 10.1016/j.imbio.2011.03.013
Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 348:15–23
doi: 10.1056/NEJMoa020696
Mirowska-Guzel D, Gromadzka G, Kurowska K, Czlonkowski A, Czlonkowska A (2010) Long-term effect of high doses glucocorticosteroids on mRNA expression for IL-6 and IL-8 in relapsed multiple sclerosis patients. Immunopharmacology and immunotoxicology 32:416–421
pubmed: 20095806
doi: 10.3109/08923970903486625
Modi WS, Dean M, Seuanez HN, Mukaida N, Matsushima K, O'Brien SJ (1990) Monocyte-derived neutrophil chemotactic factor (MDNCF/IL-8) resides in a gene cluster along with several other members of the platelet factor 4 gene superfamily. Human genetics 84:185–187
pubmed: 1967588
doi: 10.1007/BF00208938
Mohan H, Friese A, Albrecht S, Krumbholz M, Elliott CL, Arthur A, Menon R, Farina C, Junker A, Stadelmann C (2014) Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination. Acta neuropathologica communications 2:178
doi: 10.1186/s40478-014-0168-9
Moll NM, Cossoy MB, Fisher E, Staugaitis SM, Tucky BH, Rietsch AM, Chang A, Fox RJ, Trapp BD, Ransohoff RM (2009) Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Archives of neurology 66:44–53
pubmed: 19139298
pmcid: 2792736
doi: 10.1001/archneurol.2008.512
Moreira M, Tilbery C, Monteiro L, Teixeira M, Teixeira A (2006) Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta neurologica scandinavica 114:109–113
pubmed: 16867033
doi: 10.1111/j.1600-0404.2006.00629.x
Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M (1990) Neutrophil-activating properties of the melanoma growth-stimulatory activity. The Journal of experimental medicine 171:1797–1802
pubmed: 2185333
doi: 10.1084/jem.171.5.1797
Müller AM, Jun E, Conlon H, Sadiq SA (2012) Cerebrospinal hepatocyte growth factor levels correlate negatively with disease activity in multiple sclerosis. Journal of neuroimmunology 251:80–86
pubmed: 22771249
doi: 10.1016/j.jneuroim.2012.06.008
Muzio L, Cavasinni F, Marinaro C, Bergamaschi A, Bergami A, Porcheri C, Cerri F, Dina G, Quattrini A, Comi G (2010) Cxcl10 enhances blood cells migration in the sub-ventricular zone of mice affected by experimental autoimmune encephalomyelitis. Molecular and Cellular Neuroscience 43:268–280
pubmed: 19969087
doi: 10.1016/j.mcn.2009.11.008
Nakajima H, Fukuda K, Doi Y, Sugino M, Kimura F, Hanafusa T, Ikemoto T, Shimizu A (2004) Expression of TH1/TH2-related chemokine receptors on peripheral T cells and correlation with clinical disease activity in patients with multiple sclerosis. European neurology 52:162–168
pubmed: 15528917
doi: 10.1159/000081856
Neuteboom RF, Verbraak E, Voerman JS, Van Meurs M, Steegers EA, De Groot CJ, Laman JD, Hintzen RQ (2009) First trimester interleukin 8 levels are associated with postpartum relapse in multiple sclerosis. Multiple Sclerosis Journal 15:1356–1358
pubmed: 19797262
doi: 10.1177/1352458509107009
Nomiyama H, Osada N, Yoshie O (2010) The evolution of mammalian chemokine genes. Cytokine & growth factor reviews 21:253–262
doi: 10.1016/j.cytogfr.2010.03.004
Nomiyama H, Osada N, Yoshie O (2011) A family tree of vertebrate chemokine receptors for a unified nomenclature. Developmental & Comparative Immunology 35:705–715
doi: 10.1016/j.dci.2011.01.019
Oettgen, H. & Broide, D. H. 2011. Introduction to mechanisms of allergic. Allergy E-Book: Expert Consult Online and Print, 1.
Omari KM, John G, Lango R, Raine CS (2006) Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 53:24–31
pubmed: 16086366
doi: 10.1002/glia.20246
Ottoboni L, Frohlich IY, Lee M, Healy BC, Keenan BT, Xia Z, Chitnis T, Guttmann CR, Khoury SJ, Weiner HL (2013) Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology 81:1891–1899
pubmed: 24174586
pmcid: 3843384
doi: 10.1212/01.wnl.0000436612.66328.8a
Pashenkov M, Söderström M, Link H (2003) Secondary lymphoid organ chemokines are elevated in the cerebrospinal fluid during central nervous system inflammation. Journal of Neuroimmunology 135:154–160
pubmed: 12576236
doi: 10.1016/S0165-5728(02)00441-1
Patel JR, Mccandless EE, Dorsey D, Klein RS (2010) CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination. Proceedings of the National Academy of Sciences 107:11062–11067
doi: 10.1073/pnas.1006301107
Patel JR, Williams JL, Muccigrosso MM, Liu L, Sun T, Rubin JB, Klein RS (2012) Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNS. Acta neuropathologica 124:847–860
pubmed: 22933014
pmcid: 3508279
doi: 10.1007/s00401-012-1034-0
Perry, J. S., Han, S., Xu, Q., Herman, M. L., Kennedy, L. B., Csako, G. & Bielekova, B. 2012. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Science translational medicine, 4, 145ra106-145ra106.
Petković F, Blaževski J, Momčilović M, Mostarica Stojkovic M, Miljković D (2013) Nitric oxide inhibits CXCL12 expression in neuroinflammation. Immunology and cell biology 91:427–434
pubmed: 23732617
doi: 10.1038/icb.2013.23
Pollok K, Mothes R, Ulbricht C, Liebheit A, Gerken JD, Uhlmann S, Paul F, Niesner R, Radbruch H, Hauser AE (2017) The chronically inflamed central nervous system provides niches for long-lived plasma cells. Acta neuropathologica communications 5:88
pubmed: 29178933
pmcid: 5702095
doi: 10.1186/s40478-017-0487-8
Prat A, Biernacki K, Lavoie J-F, Poirier J, Duquette P, Antel JP (2002) Migration of multiple sclerosis lymphocytes through brain endothelium. Archives of neurology 59:391–397
pubmed: 11890842
doi: 10.1001/archneur.59.3.391
Prins M, Dutta R, Baselmans B, Brevé JJ, Bol JG, Deckard SA, Van Der Valk P, Amor S, Trapp BD, De Vries HE (2014a) Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of Multiple Sclerosis patients. Acta neuropathologica communications 2:98
pubmed: 25149422
pmcid: 4158064
doi: 10.1186/s40478-014-0098-6
Prins M, Dutta R, Baselmans B, Brevé JJP, Bol JGJM, Deckard SA, Van Der Valk P, Amor S, Trapp BD, De Vries HE, Drukarch B, Van Dam A-M (2014b) Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of Multiple Sclerosis patients. Acta neuropathologica communications 2:98–98
pubmed: 25149422
pmcid: 4158064
doi: 10.1186/s40478-014-0098-6
Puthenparampil M, Federle L, Miante S, Zito A, Toffanin E, Ruggero S, Ermani M, Pravato S, Poggiali D, Perini P (2017) BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset. Journal of neuroinflammation 14:11
pubmed: 28095856
pmcid: 5240243
doi: 10.1186/s12974-016-0785-2
Ragheb S, Li Y, Simon K, Vanhaerents S, Galimberti D, De Riz M, Fenoglio C, Scarpini E, Lisak R (2011) Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Multiple Sclerosis Journal 17:819–829
pubmed: 21372118
doi: 10.1177/1352458511398887
Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F (2009) CC chemokine receptor 6–regulated entry of T H-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nature immunology 10:514
pubmed: 19305396
doi: 10.1038/ni.1716
Rentzos M, Nikolaou C, Rombos A, Evangelopoulos ME, Kararizou E, Koutsis G, Zoga M, Dimitrakopoulos A, Tsoutsou A, Sfangos C (2008) Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse. Clinical neurology and neurosurgery 110:992–996
pubmed: 18657352
doi: 10.1016/j.clineuro.2008.06.005
Rossi S, Motta C, Studer V, Macchiarulo G, Germani G, Finardi A, Furlan R, Martino G, Centonze D (2015) Subclinical central inflammation is risk for RIS and CIS conversion to MS. Multiple Sclerosis Journal 21:1443–1452
pubmed: 25583841
doi: 10.1177/1352458514564482
Rossi S, Motta C, Studer V, Rocchi C, Macchiarulo G, Barbieri F, Marfia G, Furlan R, Martino G, Mancino R (2014) Interleukin-8 is associated with acute and persistent dysfunction after optic neuritis. Multiple Sclerosis Journal 20:1841–1850
pubmed: 24876157
doi: 10.1177/1352458514537365
Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, Chao C-C, Patel B, Yan R, Blain M (2016) Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nature medicine 22:586
pubmed: 27158906
pmcid: 4899206
doi: 10.1038/nm.4106
Rumble JM, Huber AK, Krishnamoorthy G, Srinivasan A, Giles DA, Zhang X, Wang L, Segal BM (2015) Neutrophil-related factors as biomarkers in EAE and MS. Journal of Experimental Medicine 212:23–35
doi: 10.1084/jem.20141015
Ruprecht K, Kuhlmann T, Seif F, Hummel V, Kruse N, Brück W, Rieckmann P (2001) Effects of oncostatin M on human cerebral endothelial cells and expression in inflammatory brain lesions. Journal of Neuropathology & Experimental Neurology 60:1087–1098
doi: 10.1093/jnen/60.11.1087
Safa A, Rashidinejad H, Khalili M, Dabiri S, Nemati M, Mohammadi M, Jafarzadeh A (2016) Higher circulating levels of chemokines CXCL10, CCL20 and CCL22 in patients with ischemic heart disease. Cytokine 83:147–157
pubmed: 27152707
doi: 10.1016/j.cyto.2016.04.006
Salmaggi A, Gelati M, Dufour A, Corsini E, Pagano S, Baccalini R, Ferrero E, Scabini S, Silei V, Ciusani E (2002) Expression and modulation of IFN-γ-inducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis. Journal of interferon & cytokine research 22:631–640
doi: 10.1089/10799900260100114
Sanseverino I, Rinaldi AO, Purificato C, Cortese A, Millefiorini E, Gessani S, Gauzzi MC (2014) CCL2 induction by 1, 25 (OH) 2D3 in dendritic cells from healthy donors and multiple sclerosis patients. The Journal of steroid biochemistry and molecular biology 144:102–105
pubmed: 24184699
doi: 10.1016/j.jsbmb.2013.10.018
Saruhan-Direskeneli G, Yentür SP, Akman-Demir G, Işik N, Serdaroğlu P (2003) Cytokines and chemokines in neuro-Behçet's disease compared to multiple sclerosis and other neurological diseases. Journal of neuroimmunology 145:127–134
pubmed: 14644038
doi: 10.1016/j.jneuroim.2003.08.040
Scarpini E, Galimberti D, Baron P, Clerici R, Ronzoni M, Conti G, Scarlato G (2002) IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. Journal of the neurological sciences 195:41–46
pubmed: 11867072
doi: 10.1016/S0022-510X(01)00680-3
Schrader A, Lechner O, Templin M, Dittmar K, Machtens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak T, Gatzlaff P (2002) CXCR4/CXCL12 expression and signalling in kidney cancer. British journal of cancer 86:1250–1256
pubmed: 11953881
pmcid: 2375348
doi: 10.1038/sj.bjc.6600221
Sellebjerg F, Börnsen L, Khademi M, Krakauer M, Olsson T, Frederiksen J, Sørensen P (2009a) Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73:2003–2010
pubmed: 19996075
doi: 10.1212/WNL.0b013e3181c5b457
Sellebjerg F, Krakauer M, Hesse D, Ryder L, Alsing I, Jensen P, Koch-Henriksen N, Svejgaard A, Soelberg Sørensen P (2009b) Identification of new sensitive biomarkers for the in vivo response to interferon-β treatment in multiple sclerosis using DNA-array evaluation. European journal of neurology 16:1291–1298
pubmed: 19558503
doi: 10.1111/j.1468-1331.2009.02716.x
Şen M, Akbayir E, Mercan Ö, Arsoy E, Gencer M, Yilmaz V, Küçükali Cİ, Tüzün E, Türkoğlu R (2019) Cytokine–chemokine and cognitive profile of multiple sclerosis patients with predominant optic nerve and spinal cord involvement. The journal of spinal cord medicine, 1-7
Sexton M, Cudaback E, Abdullah RA, Finnell J, Mischley LK, Rozga M, Lichtman AH, Stella N (2014) Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Inflammopharmacology 22:295–303
pubmed: 25135301
pmcid: 4170074
doi: 10.1007/s10787-014-0214-z
Seyedzadeh MH, Safari Z, Zare A, Navashenaq JG, Kardar GA, Khorramizadeh MR (2014) Study of curcumin immunomodulatory effects on reactive astrocyte cell function. International immunopharmacology 22:230–235
pubmed: 24998635
doi: 10.1016/j.intimp.2014.06.035
Sharma P, Azebi S, England P, Christensen T, Møller-Larsen A, Petersen T, Batsche E, Muchardt C (2012) Citrullination of histone H3 interferes with HP1-mediated transcriptional repression. PLoS genetics, 8.
Shimizu Y, Ota K, Kubo S, Kabasawa C, Kobayashi M, Ohashi T, Uchiyama S (2011) Association of Th1/Th2-related chemokine receptors in peripheral T cells with disease activity in patients with multiple sclerosis and neuromyelitis optica. European neurology 66:91–97
pubmed: 21846991
doi: 10.1159/000329576
Simpson J, Newcombe J, Cuzner M, Woodroofe M (1998) Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. Journal of neuroimmunology 84:238–249
pubmed: 9628469
doi: 10.1016/S0165-5728(97)00208-7
Simpson J, Newcombe J, Cuzner M, Woodroofe M (2000a) Expression of the interferon-γ-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathology and applied neurobiology 26:133–142
pubmed: 10840276
doi: 10.1046/j.1365-2990.2000.026002133.x
Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroofe MN (2000b) Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. Journal of neuroimmunology 108:192–200
pubmed: 10900353
doi: 10.1016/S0165-5728(00)00274-5
Sindern E, Patzold T, Ossege LM, Gisevius A, Malin J-P (2002) Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing–remitting multiple sclerosis. Journal of neuroimmunology 131:186–190
pubmed: 12458051
doi: 10.1016/S0165-5728(02)00263-1
Sisay S, Lopez-Lozano L, Mickunas M, Quiroga-Fernández A, Palace J, Warnes G, Lafuente RA, Dua P, Meier U-C (2017) Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS. Journal of neuroimmunology 306:40–45
pubmed: 28385186
doi: 10.1016/j.jneuroim.2017.02.017
Soleimani M, Soleymani A, Seyyedirad N (2019) Elevated CSF concentration of CCL3 and CCL4 in relapsing remitting multiple sclerosis patients. Journal of Immunoassay and Immunochemistry 40:378–385
pubmed: 31268406
doi: 10.1080/15321819.2019.1613242
Sørensen TL, Ransohoff R, Strieter R, Sellebjerg F (2004) Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. European journal of neurology 11:445–449
pubmed: 15257681
doi: 10.1111/j.1468-1331.2004.00796.x
Sørensen TL, Sellebjerg F, Jensen C, Strieter R, Ransohoff R (2001) Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. European journal of neurology 8:665–672
pubmed: 11784351
doi: 10.1046/j.1468-1331.2001.00327.x
Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM (1999) Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. The Journal of clinical investigation 103:807–815
pubmed: 10079101
pmcid: 408141
doi: 10.1172/JCI5150
Sørensen TL, Trebst C, Kivisäkk P, Klaege KL, Majmudar A, Ravid R, Lassmann H, Olsen DB, Strieter RM, Ransohoff RM (2002) Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. Journal of neuroimmunology 127:59–68
pubmed: 12044976
doi: 10.1016/S0165-5728(02)00097-8
Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, Bassil R, Croci DO, Cerliani JP, Delacour D (2012) Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 37:249–263
pubmed: 22884314
pmcid: 3428471
doi: 10.1016/j.immuni.2012.05.023
Stilund, M., Gjelstrup, M. C., Petersen, T., Møller, H. J., Rasmussen, P. V. & Christensen, T. 2015. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PloS one, 10.
Stoolman JS, Duncker PC, Huber AK, Segal BM (2014) Site-specific chemokine expression regulates central nervous system inflammation and determines clinical phenotype in autoimmune encephalomyelitis. The Journal of Immunology 193:564–570
pubmed: 24928987
doi: 10.4049/jimmunol.1400825
Szczucinski A, Losy J (2004) Long-term effect of IFN-beta 1a therapy on CCL2 (MCP-1) chemokine in patients with multiple sclerosis. Folia neuropathologica 42:15–18
pubmed: 15119740
Tamtaji OR, Kouchaki E, Salami M, Aghadavod E, Akbari E, Tajabadi-Ebrahimi M, Asemi Z (2017) The effects of probiotic supplementation on gene expression related to inflammation, insulin, and lipids in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Nutrition 36:660–665
pubmed: 28922099
doi: 10.1080/07315724.2017.1347074
Tejera-Alhambra M, Casrouge A, De Andrés C, Seyfferth A, Ramos-Medina R, Alonso B, Vega J, Fernández-Paredes L, Albert ML, Sánchez-Ramón S (2015) Plasma biomarkers discriminate clinical forms of multiple sclerosis. PLoS One, 10
Topping J, Dobson R, Lapin S, Maslyanskiy A, Kropshofer H, Leppert D, Giovannoni G, Evdoshenko E (2016) The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Multiple sclerosis and related disorders 6:49–53
pubmed: 27063622
doi: 10.1016/j.msard.2016.01.001
Trebst C, Sørensen TL, Kivisäkk P, Cathcart MK, Hesselgesser J, Horuk R, Sellebjerg F, Lassmann H, Ransohoff RM (2001) CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. The American journal of pathology 159:1701–1710
pubmed: 11696431
pmcid: 1867058
doi: 10.1016/S0002-9440(10)63017-9
Tsutsui M, Hirase R, Miyamura S, Nagayasu K, Nakagawa T, Mori Y, Shirakawa H, Kaneko S (2018) TRPM2 exacerbates central nervous system inflammation in experimental autoimmune encephalomyelitis by increasing production of CXCL2 chemokines. Journal of Neuroscience 38:8484–8495
pubmed: 30201769
doi: 10.1523/JNEUROSCI.2203-17.2018
Tuller T, Atar S, Ruppin E, Gurevich M, Achiron A (2013) Common and specific signatures of gene expression and protein–protein interactions in autoimmune diseases. Genes & Immunity 14:67–82
doi: 10.1038/gene.2012.55
Uzawa A, Mori M, Hayakawa S, Masuda S, Nomura F, Kuwabara S (2010) Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica. BMC neurology 10:113
pubmed: 21067621
pmcid: 2992493
doi: 10.1186/1471-2377-10-113
Villar LM, Espiño M, Cavanillas ML, Roldán E, Urcelay E, Emilio G, Sádaba MC, Arroyo R, González-Porqué P, Álvarez-Cermeño JC (2010) Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis. Clinical Immunology 137:51–59
pubmed: 20621566
doi: 10.1016/j.clim.2010.06.007
Villarroya H, KLEIN C, Thillaye-Goldenberg B, Eclancher F (2001) Distribution in ocular structures and optic pathways of immunocompetent and glial cells in an experimental allergic encephalomyelitis (EAE) relapsing model. Journal of neuroscience research 63:525–535
pubmed: 11241588
doi: 10.1002/jnr.1047
Vyshkina T, Kalman B (2006) Analyses of a MS-associated haplotype encompassing the CCL3 gene. Journal of neuroimmunology 176:216–218
pubmed: 16712957
doi: 10.1016/j.jneuroim.2006.03.018
Wang S, Yang T, Wan J, Zhang Y, Fan Y (2017) Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission. Brain and behavior 7:e00648
pubmed: 28413701
pmcid: 5390833
doi: 10.1002/brb3.648
Wang Y, Cao Y, Mangalam AK, Guo Y, Lafrance-Corey RG, Gamez JD, Atanga PA, Clarkson BD, Zhang Y, Wang E (2016) Neuropilin-1 modulates interferon-γ-stimulated signaling in brain microvascular endothelial cells. Journal of cell science 129:3911–3921
pubmed: 27591257
pmcid: 5087664
doi: 10.1242/jcs.190702
Wang Y, Jin S, Sonobe Y, Cheng Y, Horiuchi H, Parajuli B, Kawanokuchi J, Mizuno T, Takeuchi H, Suzumura A (2014) Interleukin-1β induces blood–brain barrier disruption by downregulating sonic hedgehog in astrocytes. PloS one, 9
WOLPE SD, SHERRY B, JUERS D, DAVATELIS G, YURT RW, CERAMI A (1989) Identification and characterization of macrophage inflammatory protein 2. Proceedings of the National Academy of Sciences 86:612–616
doi: 10.1073/pnas.86.2.612
Yi H, Bai Y, Zhu X, Zhao L, Wu X, Buch S, Wang L, Chao J, Yao H (2014) IL-17A induces MIP-1α expression in primary astrocytes via Src/MAPK/PI3K/NF-kB pathways: implications for multiple sclerosis. Journal of Neuroimmune Pharmacology 9:629–641
pubmed: 24989845
doi: 10.1007/s11481-014-9553-1
Zhang J, Shi XQ, Echeverry S, Mogil JS, De Koninck Y, Rivest S (2007) Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. Journal of Neuroscience 27:12396–12406
pubmed: 17989304
doi: 10.1523/JNEUROSCI.3016-07.2007
Zhong X, Wang H, Dai Y, Wu A, Bao J, Xu W, Cheng C, Lu Z, Qiu W, Hu X (2011) Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. Journal of neuroimmunology 240:104–108
pubmed: 22036953
doi: 10.1016/j.jneuroim.2011.10.001